S.LAB (SOLOWAYS)
In this study, 102 patients will be evenly randomized into two groups: one set to receive omega-3 fatty acids and the other a placebo. The process will be blinded, ensuring that neither the researchers nor the participants will know which group they are in. Each participant will take two capsules daily for a duration of 90 days, with the active group receiving capsules containing 1000 mg of fish oil each. All participants will be instructed to maintain their usual diet, lifestyle, and medication regimen. At the beginning and end of the study, various health assessments, including lipid panels and C-reactive protein measurements, will be conducted. Additionally, DNA samples will be collected for genotyping to identify patients with specific PPARG gene polymorphisms, leading to the creation of four distinct subgroups: those receiving omega-3 with and without polymorphisms, and those receiving placebo with and without polymorphisms.
LDL Hyperlipoproteinemia
Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia
Triglyceride Storage Type I or II Disease
omega-3 fatty acids
Placebo
NA
| Study Type : | INTERVENTIONAL |
| Estimated Enrollment : | 102 participants |
| Masking : | DOUBLE |
| Primary Purpose : | TREATMENT |
| Official Title : | Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms: A Randomized, Double-blind, Placebo-controlled Trial |
| Actual Study Start Date : | 2022-02-10 |
| Estimated Primary Completion Date : | 2022-07-01 |
| Estimated Study Completion Date : | 2022-11-01 |
Information not available for Arms and Intervention/treatment
| Ages Eligible for Study: | 40 Years to 75 Years |
| Sexes Eligible for Study: | ALL |
| Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Center of New Medical Technologies
Novosibirsk, Novosibirsk Region, Russian Federation, 630090